PV Bulletin
Health Sciences Authority (HSA)Singapore

Proposed Regulation for Complementary Health Products in Singapore

HSA invites feedback on new regulatory framework for Complementary Health Products (CHP) under the Health Products Act.

PV Impact Brief

Urgency: HighConfidence: high
Relevant for
Regulatory Intelligence LeadSignal Management LeadQPPV
Processes impacted
Country ComplianceSignal Management
Action needed

Suppliers must implement new protocols for safety reporting and record-keeping as per the proposed framework.

Owner

Regulatory Intelligence Lead

Review cadence

Review before 2026-07-29.

Policy change details

Document type
Consultation
Policy status
consultation
Publication date
2026-07-01
Consultation deadline
2026-07-29
Policy change
HSA invites feedback on a proposed regulatory framework for Complementary Health Products (CHP) under the Health Products Act, aimed at strengthening oversight of product safety, quality, and duties of suppliers.

Key changes

Proposed requirements for Product Notification, Record Keeping, and Safety Reporting for CHPs.

Affected workflows

Country ComplianceSignal Management

PV impact

Suppliers of CHPs in Singapore may face new mandatory safety reporting and record-keeping requirements under the proposed framework.

View regulator source

Source document details

Extracted documents

Unable to extract linked source document: https://www.googletagmanager.com/ns.html

Evidence and confidence

Confidence: highSource updated: Jul 1, 2026

Full briefing

What changed

New mandatory safety reporting and record-keeping requirements for suppliers of Complementary Health Products (CHPs) in Singapore are proposed under the Health Products Act.

Why it matters

These requirements will strengthen the oversight of CHP products, ensuring better safety and quality standards which could impact compliance workflows for suppliers.

Practical implication

Suppliers must implement new protocols for safety reporting and record-keeping as per the proposed framework.

#Safety Signals#consultation#Health Sciences Authority#reporting_requirement#policy-change#firecrawl-policy-agent

Related updates for your role

publicSwissmedic · Switzerland · Updated Jul 1, 2026

Change to Patient Information and Information for Healthcare Professionals Templates

Urgency: High

MAHs must ensure new medicinal product information texts use updated templates by 1 July 2026 and revise existing texts at the earliest opportunity if they include instructions for use.

LabelingRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 1, 2026

Mandatory Registration for Medical Devices in Switzerland Starting 1 July 2026

Urgency: High

Manufacturers must implement processes for device registration in swissdamed before placing devices on the market, with immediate attention needed for vigilance-reportable incidents.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicHealth Sciences Authority (HSA) Singapore · Singapore · Updated Jun 30, 2026

Extension of e-labelling to P and GSL medicines

Urgency: High

Manufacturers must adjust labeling workflows to incorporate e-labelling mechanisms, such as QR codes, for P and GSL medicines by the stipulated date.

LabelingRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead, QPPV
verifiedRegulatory action: Regulatory Update / Notice
Read impact briefarrow_forward
publicSaudi Food and Drug Authority (SFDA) · Saudi Arabia · Updated Jun 28, 2026

Regulations and Requirements for Conducting Clinical Trials on Drugs (Version 4.0)

Urgency: High

Ensure compliance with updated SUSAR reporting timelines (15 days), notify SFDA of Phase IV trials within 20 working days post-IRB approval, and prepare for the financial fee of 15,000 Saudi Riyals for clinical trial evaluations.

Country ComplianceICSRRegulatory Intelligence Lead
SOP Impact3 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead, QPPV
verifiedRegulatory action: Regulation
Read impact briefarrow_forward